GlassScriptPhysician profile
Jonathan B Klahr
NPI 1487738936
$8,215.97
in general payments reported to CMS, 2019-2025
31 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,095 · 2020: $1,168 · 2021: $1,245 · 2022: $1,475 · 2023: $1,077 · 2024: $853 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,841.36 | 2019-2025 | Enbrel, Evenity, Prolia |
| Abbvie INC. | $1,208.18 | 2019-2025 | |
| Pfizer INC. | $1,074.07 | 2019-2025 | |
| Ucb, INC. | $1,010.58 | 2019-2024 | Cimzia, Bimzelx |
| Lilly USA, LLC | $658.88 | 2019-2023 | Taltz |
| Glaxosmithkline, LLC. | $347.80 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $232.00 | 2019-2022 | |
| Novo Nordisk INC | $221.59 | 2023-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $190.75 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.76 | 2019-2021 | |
| Horizon Therapeutics Plc | $146.41 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $119.72 | 2019-2023 | |
| Fidia Pharma USA INC. | $104.91 | 2019-2021 | |
| Janssen Biotech, INC. | $100.61 | 2023-2024 | Tremfya |
| Zyla Life Sciences, INC. | $85.48 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $82.64 | 2019 | |
| Radius Health, INC. | $80.50 | 2019-2023 | |
| Mallinckrodt Enterprises LLC | $78.04 | 2019 | |
| Depuy Synthes Sales INC. | $67.33 | 2021-2023 | Orthovisc |
| Sandoz INC. | $53.80 | 2023-2024 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $44.95 | 2019 | |
| Organon LLC | $40.45 | 2023 | Renflexis, Hadlima |
| Astrazeneca Pharmaceuticals LP | $38.31 | 2021 | |
| Mallinckrodt Hospital Products INC. | $37.13 | 2020 | |
| Genzyme Corporation | $35.62 | 2023 | |
| Scilex Pharmaceuticals INC. | $30.54 | 2024 | |
| Sanofi-Aventis U.S. LLC | $29.30 | 2019 | |
| Zimmer Biomet Holdings, INC. | $24.43 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Iroko Pharmaceuticals, LLC | $23.40 | 2019 | |
| Sebela Pharmaceuticals INC. | $22.81 | 2019 | |
| Aurinia Pharma U.S., INC. | $17.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Klahr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.